All News
Israel provides COVID vaccine answers for rheumatic disease patients
The question as to how autoimmune rheumatic disease patients fare with the COVID vaccine is one being asked in rheumatologists’ offices everywhere this year, and at the EULAR 2021 Virtual Congress, data presented from Israel, one of the first countries to vaccinate on a br
Read Article
RA after 70: Too Old for bioDMARDs?
In RA, the two most common peaks of incidence are thirties and fifties; however a significant percentage of patients above the age of 70 present with active RA -of early or later onset- and require adapted treatment.
Read Article
Find all your AS/Spondyloarthritis coverage from #EULAR2021 in one spot.
https://t.co/owm8LQzHXr https://t.co/5YmDFOvolF
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: RA and Cancer: Myth or Reality? Dr. Jonathan Kay ( @RheumKay )
Dr. Kay reviewed highlights from the "Oncorheumatology: the crossroads of cancer and musculoskeletal diseases" scientific session including abstract OP0187, presented at #EULAR2021.
https://t.co/KaLEZ67L5S https://t.co/6MHXyffO2W
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: The Future of Treatment of RA-ILD: Dr. David Liew ( @drdavidliew )
Dr. David Liew reviews abstract OP0124 presented at #EULAR2021
https://t.co/0dqBPRiwjA https://t.co/XR7cQhPVRw
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: IFN Scores Predict Resistance to Skin Disease During RTX Therapy in Lupus
Dr. Yuz Yusof speaks with Dr. Lucy Carter about abstract OP0134, presented at the virtual #EULAR2021 meeting.
https://t.co/pqr8uRBiRG https://t.co/lhvuYIfI34
Links:
Dr. John Cush RheumNow ( View Tweet)
What's your #EULAR2021 IQ? Answer correctly and climb the leaderboard.
https://t.co/MsI3IFFdqn https://t.co/zJ1an40Yyj
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Prevalence of Long Term HCQ in Retinal Toxicity: Dr. Kathryn Dao (@KDAO2011 )
Dr. Kathryn Dao reviews abstract OP0133, "The Prevalence and Risk Factors of Retinal Toxicity Associated with Long-Term Hydroxychloroquine Use", presented at #EULAR2021.
https://t.co/tZyXQhZgLG https://t.co/x6AfItFWEU
Links:
Dr. John Cush RheumNow ( View Tweet)
Tune in to our latest podcast on #EULAR2021 and EULAR IQ.
https://t.co/yjId7QNRRR https://t.co/F46FLEilRY
Links:
Dr. John Cush RheumNow ( View Tweet)
#EULAR2021 IL-23 & IL-12/23 coverage in one spot on RheumNow.
https://t.co/sut3zubcow https://t.co/f7XDuRyLB9
Links:
Dr. John Cush RheumNow ( View Tweet)
RA after 70: Too Old for bioDMARDs? by Dr. Aurelie Najm #EULAR2021
In RA, the two most common peaks of incidence are 30s and 50s; however a significant % of patients in 70s present with active RA -of early or later onset- and require adapted treatment.
https://t.co/w6rxT0FmlP https://t.co/fnvSQcu0Fl
Links:
Dr. John Cush RheumNow ( View Tweet)
Video: Difficult to Treat RA: Look out for Comorbidities: Dr. Aurelie Najm #EULAR2021
https://t.co/71Kx0HmmDm https://t.co/iu2p2EXNof
Links:
Dr. John Cush RheumNow ( View Tweet)
@IainBMcInnes1 @NEJM @JWatch @NEJMres360 #rheumatology #rheumtwitter #MedTwitter #VisualAbstract #WorldASDay #spondyloarthritis #psoriasis #psoriaticarhtritis #MedEd #dermatology #JAKi #EBM
https://t.co/dGRi83Wt9x https://t.co/22WacHQZpT
EnvisionRheumat ERheumat ( View Tweet)
OP0140 at #EULAR2021:
➡️Obs, prospect Nordic study characterized axSpA pts w/ high BASDAI + ASDAS & multiple bDMARD use (indicating difficult to tx dz)
➡️1 in 10 received at least 3 bDMARDs
*⃣Multiple switchers were more often F, had higher b/l dz activity, & psoriasis
@Rheumnow https://t.co/syq0szVWKe
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
⭐️TORTUGA = PII trial that showed filgotinib (Jak1-i) signif improv SPARCC MRI scores (BM edema) in the spine + SIJ vs PBO in pts w/ active AS
⭐️OP0141 = post-hoc analysis that showed stat signif ⬇️ of CANDEN MRI scores (new bone format) w/ filgot at wk12
#EULAR2021 @Rheumnow https://t.co/RIpYIMcx1Q
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
➡️Netakimab = IL17Ai approved for AS, PsA, & Pso in Russia & Belarus
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Clive Kelly presents data from INBUILD on nintedanib in progressive fibrosing RA-ILD over 52 weeks FVC decline -82.6 (41.3) mL in nintedanib vs -199.3 (36.2) mL in placebo (p=0.037) @RheumNow #EULAR2021 Abstr#OP0124 https://t.co/MZwzNoq6LC
Richard Conway RichardPAConway ( View Tweet)
⭐️JUNIPERA: RCT of SEC in active ERA & JPsA (2-18yo, most on MTX)
-Tx . (TP)1: SEC 75/100 mg till wk 12
-TP2: cont SEC or switch to PBO till wk 104
⭐️SEC efficacious on JIA ACR30/70
⭐️74% w/ resolution of enthes
⭐️Median T2flare in PBO in TP2 = 453d
LB0004 #EULAR2021 @Rheumnow https://t.co/JsG2pXz9r6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
What to tell pts about diet?
*⃣Nutrition plays a role in inflammation in RMD & co-morbidities. What you eat matters!
*⃣ LImit salt, replace w/ herbs
*⃣ Consume low glycemic index foods.
Soda ⬆️risk of RA in women
*⃣⬆️omega-3 ⬇️omega-6 (dairy, eggs)
#EULAR2021 @Rheumnow
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#EULAR2021 POS0236
Comparison of work productivity b/w CBP w & w/o AxSpA - 2 years from SPACE cohort
⭐️AxSpA showed significant ⬇️ in work productivity loss (WPL) compared to CBP wo AxSpA
Can use to counsel AxSpA patients that we have effective Rx for return to work
@RheumNow
Eric Dein ejdein1 ( View Tweet)